The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?

D. Goldsmith; A. Covic

doi:10.1111/ijcp.12261

The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?

D. Goldsmith^*, A. Covic

^*Corresponding author for this work

Parhon Hosp, Renal Dept

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	286-289
Number of pages	4
Journal	International Journal of Clinical Practice
Volume	68
Issue number	3
DOIs	https://doi.org/10.1111/ijcp.12261
Publication status	Published - Mar 2014

Keywords

CARDIOVASCULAR-DISEASE
CINACALCET HCL
HYPERPARATHYROIDISM
DIALYSIS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ijcp.12261

Cite this

@article{c1a2cdd198e049028a7edb0d48953f03,

title = "The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?",

keywords = "CARDIOVASCULAR-DISEASE, CINACALCET HCL, HYPERPARATHYROIDISM, DIALYSIS",

author = "D. Goldsmith and A. Covic",

year = "2014",

month = mar,

doi = "10.1111/ijcp.12261",

language = "English",

volume = "68",

pages = "286--289",

journal = "International Journal of Clinical Practice",

issn = "1368-5031",